Data from Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial

• DOI: 10.1158/1078-0432.c.6530079.v1
• Publication Date: 2023-04-01T06:17:45Z
• Authors: Axel Stenmark Tul...; Henri A.J. Puttonen; Martin Sjöström; Erik Holmberg; S. Laura Chang; Felix Y. Feng; Corey Speers; Lori J. Pierce; Dan Lundstedt; Fredrika Killander; Emma Niméus; Anikó Kovács; Per Karlsson
• Keywords: Tumor-infiltrating lymphocytes

<div>AbstractPurpose:<p>Tumor-infiltrating immune cells play a key role in tumor progression. The purpose of this study was to analyze whether the infiltrate predicts benefit from postoperative radiotherapy large randomized breast cancer trial.</p>Experimental Design:<p>In SweBCG91RT trial, patients with stage I and II were breast-conserving surgery (BCS) or BCS only followed for median time 15.2 years. primary quantified through two independent methods: IHC gene expression profiling. For analyses, absolute stromal area occupied by CD8<sup>+</sup> T FOXP3<sup>+</sup> cells, respectively, used define infiltrate. found be prognostic datasets pooled into groups consisting antitumoral protumoral respectively.</p>Results:<p>An response associated reduced risk recurrence predicted less adjuvant radiotherapy. interaction between phenotype significant any both analyses (<i>P</i> = 0.039 <i>P</i> 0.035) also ipsilateral 0.025).</p>Conclusions:<p>Patients an have may derive These results impact decisions regarding early cancer.</p></div>